热门资讯> 正文
指南针抑郁症资产数据公布后，迷幻药股下跌
2025-06-24 03:24
- Most companies operating in the psychedelic medicine space are down significantly after Compass Pathways (NASDAQ:CMPS) on Monday posted late-stage data on its psilocybin-based treatment for treatment-resistant depression that left many on the Street disappointed.
- atai Life Sciences (NASDAQ:ATAI), which has an oral film version of N, N-Dimethyltryptamine (DMT) in phase 2, also for treatment-resistant depression, is off ~15%.
- MindMed (NASDAQ:MNMD), which has a form of LSD in phase 3 for major depressive disorder, is down ~6%.
- Cybin (NYSE:CYBN), which has an oral, deuterated psilocin asset in phase 2 as an adjunct treatment for depression, is down ~5%.
- GH Research (NASDAQ:GHRS), which has an inhalation mebufotenin candidate in phase 2 for treatment-resistant depression, is off ~5%.
- Other names in the space that are struggling today include Clearmind Medicine (NASDAQ:CMND), Enveric Biosciences (NASDAQ:ENVB), and Bright Minds Biosciences (NASDAQ:DRUG).
More on Mind Medicine, atai Life Sciences,
- Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript
- Mind Medicine (MindMed) Inc. 2025 Q1 - Results - Earnings Call Presentation
- Mind Medicine: Strong Data, But Psychedelic Stigma Still Clouds Investor Confidence
- atai Life Sciences and Beckley Psytech merging
- Psychedelic stocks rise as FDA chief’s comments seen favorable to industry
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
